Question to the Department of Health and Social Care:

To ask Her Majesty's Government what discussions they have held, if any, with the National Institute for Health and Care Excellence (NICE) in relation to the delay in its committee meeting to discuss the use of the drug Trodelvy (sacituzumab govitecan) for certain patients living with triple negative secondary breast cancer.

The Department and the National Institute for Health and Care Excellence (NICE) have discussed the decision to reschedule the committee meeting for the appraisal of Trodelvy to June 2022. This was due to the large number of other items, including other cancer treatments, on the agenda for the meeting in May and ensuring all topics were given the appropriate time and diligence. The consultation for this appraisal received a high number of responses and NICE wishes to ensure sufficient time for the committee to consider this feedback. NICE expects to issue final guidance on Trodelvy in August 2022.